1. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial 
Keith B Allen, MD, Robert D Dowling, MD, William W Angell, MD, Deepak M Gangahar, MD, Tommy L Fudge, MD, Wayne Richenbacher, MD, Samuel L Selinger, MD, Michael R Petracek, MD, Douglas Murphy, MD 
The Annals of Thoracic Surgery 
Volume 77, Issue 4, Pages (April 2004)
DOI: /j.athoracsur

2. Fig 1
Mean Canadian Cardiovascular Society angina class in surviving patients after transmyocardial revascularization.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

3. Fig 2
Improvement in Canadian Cardiovascular Society angina class at 3 months, 1 year, and a mean of 5 years. *Comparison between transmyocardial revascularization (TMR) and medical therapy. (Crossover = patients randomized to medical therapy who met the criteria for treatment failure and underwent transmyocardial revascularization while unstable; Medical Therapy = patients randomized to medical therapy excluding crossovers; TMR = patients randomized to transmyocardial revascularization.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

4. Fig 3
Kaplan-Meier intention-to-treat survival estimates. (MMM = continued maximal medical management; TMR = transmyocardial revascularization.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

5. Fig 4
Cumulative hazard (CH) intention-to-treat analysis. (MMM = continued maximal medical management; TMR = transmyocardial revascularization.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

6. Fig 5
Kaplan-Meier 5-year survival estimates. (Crossover = patients randomized to medical therapy who met the criteria for treatment failure and underwent transmyocardial revascularization while unstable; Medical Therapy = patients randomized to medical therapy excluding crossovers; TMR = patients randomized to transmyocardial revascularization.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )